ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Quench Bio launches with $50 million to target inflammasome pathway protein, gasdermin-D

by Ryan Cross
February 1, 2020 | APPEARED IN VOLUME 98, ISSUE 5

 

Quench Bio, a start-up in Cambridge, Massachusetts, has raised $50 million in series A financing to develop small molecules that target gasdermin D, a protein implicated in inflammatory conditions and activated by inflammasomes. Gasdermin D kills cells by forming rings that poke holes in the cell membrane, causing the cells to burst and release inflammatory molecules. Quench hopes that inhibiting gasdermin D will help treat diseases like rheumatoid arthritis, lupus, multiple sclerosis, and nonalcoholic steatohepatitis.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment